This trial has been completed.

Condition uremic pruritus
Treatments pa101b, placebo
Phase phase 2
Sponsor Patara Pharma
Start date February 2016
End date August 2016
Trial size 70 participants
Trial identifier NCT02696499, PA101B-UP-02


This is a randomized, double blind, placebo-controlled, parallel-arm, multi-center, Phase 2, proof-of-concept efficacy and safety study in patients with end-stage renal disease requiring hemodialysis.

The purpose of the study is to determine the efficacy and safety profile of PA101B delivered via eFlow high efficiency nebulizer in patients with uremic pruritus who are symptomatic despite using standard treatments.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose treatment
Masking participant, care provider, investigator, outcomes assessor
40 mg PA101B administered via inhalation twice daily for 7 weeks
(Placebo Comparator)
Matching placebo administered via inhalation twice daily for 7 weeks

Primary Outcomes

Itching intensity
time frame: 7 weeks

Secondary Outcomes

Pruritus-specific quality of life (QoL)
time frame: 7 weeks
Pruritus-specific sleep quality
time frame: 7 weeks
Assessment of depression
time frame: 7 weeks
Patient Global Impression of Change (PGIC)
time frame: 7 weeks

Eligibility Criteria

All participants from 18 years up to 80 years old.

Inclusion Criteria: - Diagnosis of end-stage renal disease (ESRD) requiring hemodialysis for at least 3 months prior to the Screening Period - Receiving conventional hemodialysis (i.e., not hemofiltration or hemodiafiltration) - Pruritus present for at least 6 weeks of Screening - Mean pruritus severity score on a numerical rating scale (NRS) > 4 - Patient-Assessed Disease Severity Scale Type B or C at Screening - Documentation of a urea reduction ratio (URR) >65% or single-pooled Kt/V> 1.4 during Screening - Willing and able to provide written informed consent Exclusion Criteria: - Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the patient at risk or compromise the quality of the study data as determined by the investigator - Myocardial infarction within 6 months or unstable angina, acute coronary syndrome, or interventional coronary procedure within 2 months of Screening - Upper or lower respiratory tract infection (including sinus infection) within 4 weeks of Screening - Severely symptomatic cardiopulmonary disease defined by the use of home oxygen treatment, dyspnea at rest or with minimal exertion, uncontrolled arrhythmias (e.g. atrial fibrillation with inadequate rate control), or history of life-threatening arrhythmias (e.g. cardiac arrest or syncope related to arrhythmia) - Acute exacerbation of asthma or chronic obstructive pulmonary disease resulting in hospitalization or visit to an emergency department or urgent care clinic within 6 months of Screening - Hospitalization for any medical reason other than for a pre-planned procedure or dialysis access related procedure within the 2 weeks of Screening - Malignancy requiring active treatment with a systemic drug - Participation in any other investigation drug study within 4 weeks of Screening - Current or anticipated use of baclofen, gabapentin, pregabalin and nalbuphine for the treatment of pruritus - Current or anticipated use of glucocorticoids administered intravenously, orally, or transdermally - Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study

Additional Information

Official title Treatment of Uremic Pruritus With Inhaled PA101B in Patients With End-Stage Renal Disease Requiring Hemodialysis
Description The symptom score for determining eligibility will be established during the Screening Period (up to 4 weeks) and eligible patients will be randomly allocated in a 2:1 ratio between the active and placebo arms at the baseline visit (Week 0). During the Treatment Period, clinic visits will occur at the end of Weeks 1, 3, 5 and 7. Following completion of the Treatment Period, patients will enter a 2-week Washout Period in both treatment arms. Routine hemodialysis treatment will continue according to the dialysis unit's standard practice in all patients. Patients will be allowed to continue to use the same daily doses of pre-randomization H1 antihistamines as well as the same daily doses of any other allowed medications throughout the study. Blood samples will be collected for various biomarkers. In a subset of patients, additional blood samples will be collected for pharmacokinetic assessments. Clinical safety assessments will be performed at each clinic visit.
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Patara Pharma.